Levodopa: As a precursor to dopamine, levodopa crosses the blood-brain barrier and is converted into dopamine in the brain. This increase in dopamine levels is believed to alleviate Parkinson’s disease symptoms.
Carbidopa: When administered orally, levodopa undergoes rapid peripheral conversion to dopamine, reducing its availability for the central nervous system. Carbidopa prevents this premature breakdown, thereby increasing the amount of levodopa that reaches the brain.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Supadopa TR is prescribed for managing Parkinson’s disease, post-encephalitic parkinsonism, and cases of parkinsonism induced by exposure to carbon monoxide or manganese toxicity.
For Patients New to Levodopa Treatment:
Transitioning from Immediate-Release Carbidopa-Levodopa to Supadopa TR:
Conversion Guidelines from Immediate-Release Levodopa-Carbidopa to Supadopa TR:
Immediate-Release Levodopa Dose | Converted Supadopa TR Dose | Recommended Regimen |
---|---|---|
400 mg – 549 mg | 855 mg | 3 capsules of Supadopa TR 95 mg, taken thrice daily |
550 mg – 749 mg | 1,140 mg | 4 capsules of Supadopa TR 95 mg, taken thrice daily |
750 mg – 949 mg | 1,305 mg | 3 capsules of Supadopa TR 145 mg, taken thrice daily |
950 mg – 1,249 mg | 1,755 mg | 3 capsules of Supadopa TR 195 mg, taken thrice daily |
≥ 1,250 mg | 2,340 mg – 2,205 mg | 3 capsules of Supadopa TR 245 mg, taken thrice daily |
This medication should only be taken as directed by a registered physician.
Common Side Effects:
Rare but Serious Side Effects: